The Japan-based company will be renamed The Jackson Laboratory Japan. It employs about 250 people at three production sites located in Atsugi, Hino, and Tsukuba, Japan. There is an administrative office in Yokohama, Japan, that provides research models and associated services to support clients in the Japanese market.

In a separate release, Charles River Labs announced it completed the sale of its RMS Japan operations to The Jackson Laboratory for approximately $63 million in cash, subject to customary closing adjustments.

Charles River Labs also sold its gene therapy contract development manufacturing organization site in Sweden to a private investor group for approximately $52 million in cash, with potential contingent payments of up to an additional $25 million, subject to certain adjustments, the company said.

The Jackson Laboratory offers a repository of high-quality models, including aged mice, the JAX NSG portfolio, humanized mice, and inbred strains like Black 6 and BALB/c, as well as others in its catalog of 12,000 precision research and therapeutic models, the company said. The entire JAX NSG portfolio is now available to researchers in Japan.

Charles River reports 34% revenue spike in Q2
Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.

Charles River completes Vigene acquisition
Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction...

Charles River to acquire Vigene Biosciences for $293M
Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing...